Table 3.
Clinical trials of IDHmt-targeting drugs
| Drug | Phase | Target | Completion | Histology | Inclusion | Goal |
|---|---|---|---|---|---|---|
| AG-120 | I | IDH1X | Completed | nd | Progressive | safety, MTD |
| AG-881 NCT02481154 | I | IDH1/2X | Q3 2018 | nd | Progressive | safety, MTD |
| AG-120 & AG-881 NCT03343197 | I | IDH1R132H | Q3 2020 | °II-III | Progressive, preoperative | 2HG -MRS |
| IDH305 NCT02381886 | I | IDH1X132X | Completed | °III-IV | Recurrent after RCTX | safety, MTD |
| BAY1436032 NCT02746081 | Phase I/expansion | IDH1R132X | Closed early after futility analysis | °III-IV | Recurrent after RCTX | safety, MTD |
Abbreviations: 2HG-MRS, 2-hydroxyglutarate magnetic resonance spectroscopy; nd, not detailed; MTD, maximum tolerated dose; RCTX, radiochemotherapy; Q, quarter.